In the marginal zone lymphoma trial, 70% of patients had a complete response and 91% had an overall response. As this trial is still ongoing, Lossos is presenting interim results at the conference ...

The FDA has granted Breakthrough Therapy Designation to Bayer’s PI3K inhibitor Aliqopa (copanlisib) for marginal zone lymphoma (MZL) patients who have received two prior therapies. MZL is an ...

At the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition last month, the company announced positive ...